2 completed, 1 recruiting, 1 terminated, 1 unknown. 3 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Recruiting 1, Unknown 1, Withdrawn 1 |
| Phase 1 | 2 | Completed 1, Unknown 1 |
Follow Squamous Cell Carcinoma of the Penis: new trials by email Literature Review of Squamous Cell Carcinoma of the Penis trials Research Report on Squamous Cell Carcinoma of the Penis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C... Sacituzumab govitecan, Atezolizumab - Small Cell Carcinoma of the Bladder, Small Cell Carcinoma of the Urinary Tract | Phase 2 | Recruiting | National Cancer Institute (NCI) | 60 | 2024-08-01 | 2026-10-16 |
| A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors XmAb20717 - Melanoma, Breast Carcinoma | Phase 1 | Completed | Xencor, Inc. | 150 | 2018-07-10 | 2022-12-01 |
| PEN-866 in Patients With Advanced Solid Malignancies PEN-866 Sodium, fluorouracil, Folinic acid - Carcinoma, Endometrial Adenocarcinoma | Phase 1 / Phase 2 | Unknown | Tarveda Therapeutics | 340 | 2017-08-29 | 2022-02-17 |
| Efficacy and Safety of Cetuximab in Metastatic Penile Carcinoma (PENILANE) Cetuximab, TIP - Squamous Cell Carcinoma of the Penis | Phase 2 | Withdrawn | Centre Leon Berard | 2016-02-01 | 2016-02-25 | |
| Characterising Metastatic Penile Cancer Using Molecular Imaging - Hybrid MRI-PET [MRI-PET] MRI-PET - Squamous Cell Carcinoma of the Penis | Completed | Queen Mary University of London | 78 | 2013-07-22 | 2025-03-10 | |
| Contemporary Characteristics of Penile Cancer Data Capture, Questionnaire Administration - Penile Carcinoma, Squamous Cell Carcinoma of the Penis | Terminated | M.D. Anderson Cancer Center | 499 | 2004-04-22 | 2025-09-24 |
Anus Neoplasms (2) · Carcinoma, Transitional Cell (2) · Penile Neoplasms (2) · Small Cell Lung Carcinoma (2) · Stomach Neoplasms (2) · Bile Duct Neoplasms (1) · Breast Neoplasms (1) · Carcinoma (1) · Carcinoma, Basal Cell (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Neuroendocrine (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Carcinoma, Squamous Cell (1) · Cholangiocarcinoma (1)
Neoplasms (4) · Neoplasms by Histologic Type (3) · Neoplasms by Site (3) · Neoplasms, Glandular and Epithelial (3) · Anus Diseases (2) · Bronchial Neoplasms (2) · Carcinoma (2) · Carcinoma, Bronchogenic (2) · Digestive System Diseases (2) · Digestive System Neoplasms (2) · Gastrointestinal Diseases (2) · Gastrointestinal Neoplasms (2) · Genital Diseases (2) · Genital Diseases, Male (2) · Genital Neoplasms, Male (2)
Cetuximab (1) · Fluorouracil (1) · Leucovorin (1) · atezolizumab (1) · niraparib (1) · sacituzumab govitecan (1)
Centre Leon Berard (1) · M.D. Anderson Cancer Center (1) · National Cancer Institute (NCI) (1) · Queen Mary University of London (1) · Tarveda Therapeutics (1) · Xencor, Inc. (1)
United States (4) · France (1) · United Kingdom (1)
Andrea B Apolo, M.D. (1) · Anish Thomas, MD (1) · Curtis A Pettaway (1) · Manit Arya, MBChB, FRCS (1) · Zequn Tang, MD (1)